msd p53 peptide vaccine patent peptides - is-semaglutide-in-mounjaro peptide Unraveling the MSD P53 Peptide Vaccine Patent Landscape

how-to-take-glutathione-iv The pursuit of novel cancer therapies has led to significant advancements in peptide vaccine development, particularly those targeting the p53 tumor suppressor protein. The MSD P53 peptide vaccine patent landscape reveals a focused effort to harness the potential of peptides derived from or interacting with p53 as a therapeutic strategy.Vaccibody AS This exploration delves into the granted patents, ongoing research, and the overarching intent behind these developments, aiming to provide a comprehensive overview for those seeking to understand this dynamic field.2021年4月15日—peptide vaccineGV1001 in patients with locally advanced or ... cancer (Merck); with a viral vaccine expressingp53, MVA, a vaccine ...

The p53 protein, often referred to as the "guardian of the genome," plays a crucial role in preventing cancer formation by regulating cell growth and inducing apoptosis in damaged cells.Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 ... Mutations in the p53 gene are among the most common genetic alterations found in human cancers, leading to a loss of its tumor-suppressive functions and contributing to tumor development and progression. Consequently, targeting p53 or its aberrant forms presents a compelling strategy for cancer treatment.

Patents related to MSD's involvement in P53 peptide vaccine research primarily highlight the potential of peptides derived from p53 itself to act as immunogens. For instance, patents such as AU2008257791B2 and US8663646B2 describe the use of p53-derived peptides as components of a vaccine designed to elicit an anti-cancer immune response2020 UNIVERSAL REGISTRATION DOCUMENT .... The underlying principle is to present specific p53 peptides, potentially those associated with mutations, to the immune system, thereby training it to recognize and eliminate cancer cells expressing these altered proteins. This approach aligns with the broader concept of peptide vaccines, which offer a more targeted and potentially safer alternative to traditional vaccination methods.

Beyond directly using p53 peptides as the immunogenic agent, research also explores peptides that modulate p53 activityDeveloping an Effective Peptide-Based Vaccine for COVID-19. Patents referencing p53 activator peptidomimetic macrocycles, such as those binding MDM2 and MDMX, demonstrate an interest in compounds that can restore wild-type p53 function. While these are not strictly peptide vaccines in the traditional sense, they represent an important facet of vaccine and therapeutic development that interacts with the p53 pathway.2021年11月15日—models with PLGA/PEI nanoparticles loaded with GSE4peptide. These ... Local Burden of DiseaseVaccineCoverage Collaborators. Mapping ... The ability of these peptides to be cell-permeable without significant cellular disruption (as noted in some patent descriptions) is a critical parameter for their potential therapeutic efficacy.

The search intent surrounding "MSD P53 peptide vaccine patent" clearly indicates a strong interest in the peptide and vaccine technologies, specifically concerning p53 and the associated patents.Lymph-node-targeted, mKRAS-specific amphiphile vaccine ... This includes understanding the underlying scientific principles, the types of peptides being investigated, and the intellectual property surrounding these innovations. The mention of MSD (Merck & Co., Inc.The following list identifies our company's rights in USpatentsassociated with the relevant product.) in various search results underscores its significant role in the pharmaceutical industry's engagement with cancer vaccines and related patents.

Furthermore, the broader context of peptide vaccines and vaccines in general is a significant consideration. Research into peptide vaccine formulations and their use in inducing immunity is a rapidly evolving field2022年3月29日—Non-Membrane DisruptiveP53Activating StapledPeptides– filing in ... Mara: DioSynVax, Cambridge – ML invaccinedesign. Lauren .... The inclusion of p53 as a target antigen in peptide-based vaccines, alongside other tumor-associated antigens like CEA, HER-2, and MAGE family members, is evident in trials involving various cancer types, including non-small cell lung cancer. The development of personalized peptide vaccines (PPVs), which utilize cancer peptides selected from a specific patient's tumor profile, represents a highly individualized approach within this domain.

The patent landscape also reflects the multifaceted nature of cancer vaccine development, extending to combinations with other treatment modalities. For instance, studies exploring the efficacy of p53-mutated CRC treatment in combination with established chemotherapy agents like 5-fluorouracil, with involvement from companies like MSD, highlight the integrated approach to fighting cancer.作者：SJ Dovedi·2021·被引用次数：176—Moreover, in NOD/SCID gamma (NSG) mice infused with human viral–specific T cells bearing human viralpeptide–transduced OE21 tumors, treatment with MEDI5752 ... Similarly, the development of vaccine compositions aimed at restoring immune pathways, such as the NKG2D pathway, demonstrate a commitment to robust anti-tumor immunity.

In summary, the MSD P53 peptide vaccine patent inquiry points to a significant area of research and development focused on leveraging p53 as a therapeutic target through peptide vaccine strategies. The analysis of granted patents and ongoing research indicates a commitment to developing innovative vaccines that can elicit targeted immune responses against canceriNeo-Vac-P01 Personalized NeoantigenPeptide Vaccine· iNeo-Vac-R01 · Inetetamab ...p53Protein Therapy - Anser ·P53Targeting Therapy - Onco3R · P552-02 .... The exploration of both direct p53-targeting peptides and modulating agents, coupled with advancements in peptide vaccine design and personalized approaches, paints a promising, albeit complex, picture for the future of cancer immunotherapy2023年10月26日—...MSD, and Mundipharma in the last 5y. No other potential conflict of ...patentapplications filed by Nuclidium AG and the. University of .... The continued issuance and exploration of vaccine patents in this space by key players like MSD are indicative of the ongoing drive to translate these scientific breakthroughs into tangible patient benefits.“Induction ofp53-specific immunity by ap53synthetic longpeptide vaccinein patients treated for metastatic colorectal cancer. ... https://patents.google.com/ ...